Acute Myeloid Leukemia: Debate on Standard of Care for Patients ≥ 60 Years

Earn CME for related activities: https://www.naccme.com/oln

In this webcast from the 'Looking to the Future With Hope: Advances in the Treatment of AML' symposium during the 2019 Lymphoma & Myeloma conference in New York, Drs. Pinkal Desai and Sangmin Lee debate whether venetoclax + azacitidine/decitabine/LDAC should be the new standard of care for acute myeloid leukemia (AML) patients greater than equal to 60 years of age.

© 2019 Imedex, an HMP Company